Skip to content

Computer-delivered Screening & Brief Intervention for Marijuana Use in Pregnancy

Computer-based Screening, Brief Intervention, and Referral to Treatment (SBIRT) for Marijuana Use in Pregnancy: Planning a Stage II Trial

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT02191605
Enrollment
60
Registered
2014-07-16
Start date
2015-09-30
Completion date
2017-10-27
Last updated
2018-07-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Marijuana Use, Pregnancy

Keywords

Computerized Brief Intervention

Brief summary

Marijuana is by far the mostly commonly used illicit drug during pregnancy, and prenatal exposure to marijuana can have lasting negative effects. However, current answers to this problem are failing to reach most women who use marijuana while pregnant. This project will develop and begin testing two technology-based, highly practical interventions that could reduce the number of children who are prenatally exposed to marijuana.

Detailed description

There are at present no evidence-based interventions for marijuana use during pregnancy, despite its being by far the most commonly used illicit drug during pregnancy (particularly among African-American women), and despite growing evidence that it may have a range of long-term cognitive and neurobehavioral consequences. This R34 clinical trial planning grant therefore proposes the development and preliminary validation of two high- reach and mutually compatible technology-based interventions for marijuana use during pregnancy. The first, a theory-based, synchronous, and highly interactive computer-delivered brief intervention, will be based on an emerging knowledge base regarding key elements of efficacious technology-delivered interventions. The second intervention, a series of tailored text messages, will build on the rich literature regarding key tailoring elements. These interventions will be developed and refined with input from pregnant women who report active use of marijuana, as well as from health care providers. They will subsequently be tested-alone and in combination-in a pilot randomized trial involving 80 women actively using marijuana during pregnancy. This Stage I pilot work would set the stage for a confirmatory Stage II trial. It would also produce the first high-reach brief interventions for marijuana use during pregnancy. If effective, these approaches could have a substantial population impact on marijuana use among pregnant women, with potential for lifelong improved outcomes for both mother and child.

Interventions

BEHAVIORALeSBIRT

A single 20 minute interactive computer-delivered intervention designed to promote motivation to change prenatal marijuana use, without presuming the participant to be currently using marijuana while pregnant.

BEHAVIORALTailored texting

Group text messaging software from Trumpia, Inc. will be used to create the tailored text messages that will be sent to participants assigned to this intervention. Text messages will sent after the initial study participation visit until childbirth or participant opts out of receiving them.

Sponsors

National Institutes of Health (NIH)
CollaboratorNIH
National Institute on Drug Abuse (NIDA)
CollaboratorNIH
Wayne State University
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
DOUBLE (Subject, Outcomes Assessor)

Eligibility

Sex/Gender
FEMALE
Age
18 Years to 40 Years
Healthy volunteers
No

Inclusion criteria

* 18 to 40 years of age * 20 weeks or less gestation * intention to carry pregnancy to term * self-reported marijuana use in month before pregnancy * own a cell phone and willingness to receive text messages * gives consent to access medical records for collection of birth outcome data

Exclusion criteria

* frank cognitive impairment or psychosis * not able to communicate in English * not planning to deliver at a Detroit Medical Center (DMC) hospital * previous or current participant in a study conducted by Dr. Ondersma * Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) Perinatal Research Branch participant.

Design outcomes

Primary

MeasureTime frameDescription
Number of Participants Abstinent From Marijuana for the 7 Days Prior to Deliveryself-reported use during 7 days prior to delivery of their babyMarijuana use will be measured at the time of delivery of their infant by self-report (TimeLine Follow Back interview - TLFB) and urine analysis. This will represent the number of participants who abstinent (reported no marijuana use and had a negative toxicology urine screen) from marijuana for the 7 days prior to delivery.
Number of Participants Abstinent From Marijuana for the 90 Days Prior to Deliveryself-reported use during 90 days prior to delivery of their babyMarijuana use will be measured at the time of delivery of their infant by self-report (TimeLine Follow Back interview - TLFB) and hair toxicology analysis. This will represent the number of participants who were abstinent (reported no marijuana use and had a negative hair toxicology results) from marijuana for the 90 days prior to delivery.

Countries

United States

Participant flow

Participants by arm

ArmCount
Electronic SBIRT (eSBIRT)
Participants in this condition will receive empathic exploration of their thoughts regarding marijuana use, provision of information on possible consequences of marijuana use during pregnancy and potential benefits of changing use (with permission), normed feedback, use of Motivational Interviewing techniques to elicit their own reasons for change, video testimonials modeling successful change, and information on change methods with optional goal setting. eSBIRT: A single 20 minute interactive computer-delivered intervention designed to promote motivation to change prenatal marijuana use, without presuming the participant to be currently using marijuana while pregnant.
15
Tailored Texting
Participants in this condition will chose the frequency and time of text messages that will continue until childbirth or the participant opts out. The text messages will be a mix of marijuana targeted content (without directly referring to marijuana in a way that implies use by the participant) and general content related to healthy pregnancy; using appropriate humor and tips for community resources. Tailoring will focus on gestational age, self-efficacy, and social support. Tailored texting: Group text messaging software from Trumpia, Inc. will be used to create the tailored text messages that will be sent to participants assigned to this intervention. Text messages will sent after the initial study participation visit until childbirth or participant opts out of receiving them.
15
eSBIRT & Texting
Participants in this arm will receive both the computerized intervention and tailored text messaging intervention as described in the eSBIRT and Tailored texting arms. eSBIRT: A single 20 minute interactive computer-delivered intervention designed to promote motivation to change prenatal marijuana use, without presuming the participant to be currently using marijuana while pregnant. Tailored texting: Group text messaging software from Trumpia, Inc. will be used to create the tailored text messages that will be sent to participants assigned to this intervention. Text messages will sent after the initial study participation visit until childbirth or participant opts out of receiving them.
15
Assessment Only
Participants in the arm will participant in screening and the baseline assessment conducted on the computer only. They will not receive an intervention.
8
Screening Only
Participants in this arm of the study will only answer the screening questions and will not be asked the baseline assessment or participate in an intervention.
7
Total60

Withdrawals & dropouts

PeriodReasonFG000FG001FG002FG003FG004
Overall StudyLost to Follow-up94734

Baseline characteristics

CharacteristicElectronic SBIRT (eSBIRT)Tailored TextingeSBIRT & TextingAssessment OnlyScreening OnlyTotal
Age, Continuous24.3 years
STANDARD_DEVIATION 5.9
23.5 years
STANDARD_DEVIATION 3.7
27.2 years
STANDARD_DEVIATION 5.4
22.6 years
STANDARD_DEVIATION 3.2
NA years24.6 years
STANDARD_DEVIATION 5
ASSIST marijuana score9 scores on a scale9 scores on a scale6 scores on a scale6 scores on a scaleNA scores on a scale8 scores on a scale
Ethnicity (NIH/OMB)
Hispanic or Latino
1 Participants0 Participants0 Participants0 Participants0 Participants1 Participants
Ethnicity (NIH/OMB)
Not Hispanic or Latino
14 Participants15 Participants15 Participants8 Participants7 Participants59 Participants
Ethnicity (NIH/OMB)
Unknown or Not Reported
0 Participants0 Participants0 Participants0 Participants0 Participants0 Participants
Race (NIH/OMB)
American Indian or Alaska Native
0 Participants0 Participants0 Participants0 Participants0 Participants0 Participants
Race (NIH/OMB)
Asian
0 Participants0 Participants0 Participants0 Participants0 Participants0 Participants
Race (NIH/OMB)
Black or African American
11 Participants12 Participants15 Participants8 Participants5 Participants51 Participants
Race (NIH/OMB)
More than one race
3 Participants1 Participants0 Participants0 Participants1 Participants5 Participants
Race (NIH/OMB)
Native Hawaiian or Other Pacific Islander
0 Participants0 Participants0 Participants0 Participants0 Participants0 Participants
Race (NIH/OMB)
Unknown or Not Reported
0 Participants0 Participants0 Participants0 Participants0 Participants0 Participants
Race (NIH/OMB)
White
1 Participants2 Participants0 Participants0 Participants1 Participants4 Participants
Sex: Female, Male
Female
15 Participants15 Participants15 Participants8 Participants7 Participants60 Participants
Sex: Female, Male
Male
0 Participants0 Participants0 Participants0 Participants0 Participants0 Participants

Adverse events

Event typeEG000
affected / at risk
EG001
affected / at risk
EG002
affected / at risk
EG003
affected / at risk
EG004
affected / at risk
deaths
Total, all-cause mortality
0 / 150 / 150 / 150 / 80 / 7
other
Total, other adverse events
0 / 150 / 150 / 150 / 80 / 7
serious
Total, serious adverse events
0 / 150 / 150 / 150 / 80 / 7

Outcome results

Primary

Number of Participants Abstinent From Marijuana for the 7 Days Prior to Delivery

Marijuana use will be measured at the time of delivery of their infant by self-report (TimeLine Follow Back interview - TLFB) and urine analysis. This will represent the number of participants who abstinent (reported no marijuana use and had a negative toxicology urine screen) from marijuana for the 7 days prior to delivery.

Time frame: self-reported use during 7 days prior to delivery of their baby

ArmMeasureValue (COUNT_OF_PARTICIPANTS)
Electronic SBIRT (eSBIRT)Number of Participants Abstinent From Marijuana for the 7 Days Prior to Delivery6 Participants
Tailored TextingNumber of Participants Abstinent From Marijuana for the 7 Days Prior to Delivery7 Participants
eSBIRT & TextingNumber of Participants Abstinent From Marijuana for the 7 Days Prior to Delivery6 Participants
Assessment OnlyNumber of Participants Abstinent From Marijuana for the 7 Days Prior to Delivery3 Participants
Screening OnlyNumber of Participants Abstinent From Marijuana for the 7 Days Prior to Delivery2 Participants
Primary

Number of Participants Abstinent From Marijuana for the 90 Days Prior to Delivery

Marijuana use will be measured at the time of delivery of their infant by self-report (TimeLine Follow Back interview - TLFB) and hair toxicology analysis. This will represent the number of participants who were abstinent (reported no marijuana use and had a negative hair toxicology results) from marijuana for the 90 days prior to delivery.

Time frame: self-reported use during 90 days prior to delivery of their baby

ArmMeasureValue (COUNT_OF_PARTICIPANTS)
Electronic SBIRT (eSBIRT)Number of Participants Abstinent From Marijuana for the 90 Days Prior to Delivery2 Participants
Tailored TextingNumber of Participants Abstinent From Marijuana for the 90 Days Prior to Delivery5 Participants
eSBIRT & TextingNumber of Participants Abstinent From Marijuana for the 90 Days Prior to Delivery1 Participants
Assessment OnlyNumber of Participants Abstinent From Marijuana for the 90 Days Prior to Delivery2 Participants
Screening OnlyNumber of Participants Abstinent From Marijuana for the 90 Days Prior to Delivery2 Participants

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026